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Intravesical radiofrequency-induced hyperthermia combined with
chemotherapy for non-muscle-invasive bladder cancer
Hans van Valenberg1, Renzo Colombo2, & Fred Witjes1
1Department of Urology, Radboud University Medical Centre, Nijmegen, Netherlands and 2Department of Urology, University ‘Vita-Salute’
San Raffaele, Milan, Italy
Abstract
Although many treatment modalities and schedules for non-muscle-invasive bladder cancer
(NMIBC) exist, all yet prove to have limitations. Therefore the search for new forms of therapy
continues. One of these forms consists of combining intravesical chemotherapy, typically
mitomycin C (MMC), with hyperthermia achieved by a microwave-applicator. We aimed to
review the current status of intravesical radiofrequency (RF) induced chemohyperthermia (CHT)
for NMIBC with regard to efficacy, adverse-events (AEs) and its future perspective. A search for
RF-induced CHT in MEDLINE, Embase, Cochrane and ClinicalTrials.gov databases was
performed. Relevant conference abstracts were searched for manually. If applicable, experts
on the area were consulted. Papers were selected based on abstract and title. A table of newly
published clinical trials since 2011 was constructed. No meta-analysis could be performed
based on these new papers. Efficacy proved to be better for RF-induced CHT compared to both
MMC alone and bacillus Calmette–Gue´rin (BCG) instillations, with the latter being based on just
one abstract of a randomised controlled trial. The AE rate in CHT is higher compared to MMC
instillation, but is similar compared to BCG, albeit different in the type of AE. In almost all
studies no severe AEs are reported. Although heterogeneity in methodology exists, RF-induced
CHT seems promising. However, alternative methods of applying hyperthermia are starting to
present their first results, imposing as effective options too. Intravesical RF-induced CHT may
become an alternative for BCG instillation, and possibly for cystectomy, although further level 1
evidence is required for both reliable and reproducible data on efficacy and adverse events.
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Introduction
Bladder cancer is the most common malignancy of the urinary
tract. In the European Union (EU), the age-standardised
incidence rate varies from 6 per 100 000 in women to 27 per
100 000 in men [1]. These rates vary per region within the EU.
On top of the high incidence, bladder cancer was the eighth
most common cause of cancer-specific mortality in 2008.
On presentation, about 75% of patients are diagnosed with
non-muscle-invasive bladder cancer (NMIBC). In these
patients urothelial cell carcinoma is confined to the mucosa
(stage Ta, carcinoma in situ (CIS)) or invades the lamina
propria only (stage T1). The remaining patients present with
muscle-invasive disease (T 2) which can be treated with
radical cystectomy (RC), radiotherapy or systemic chemo-
therapy, depending on the presence and extent of regionally or
distantly spread disease.
Fortunately, both incidence and mortality are decreasing in
some registries, possibly reflecting a decreased prevalence of
smoking, less occupational exposure to causative agents, and
improved care. As opposed to muscle-invasive bladder cancer
(MIBC), NMIBC has a high prevalence due to relatively low
progression rates (5-year progression rate of 1–45% (0–30%
in the Club Urolo´gico Espan˜ol de Tratamiento Oncolo´gico
(CUETO) risk tables), depending on grade, stage, tumour
size, number of tumours, presence of CIS, previous recur-
rences according to the European Organization for Research
and Treatment of Cancer (EORTC) risk tables [2] and
additionally sex and age according to the CUETO risk tables
[3]) and thus has a long patient survival. However, 5-year
recurrence rates can be as high as 78%, necessitating a
frequent and long-term follow-up with outpatient clinic visits,
cytology tests, and invasive cystoscopies. This imposes a
significant burden on the patient and on the healthcare system
in both financial and logistic way.
To prevent recurrence and progression from occurring,
adjuvant treatment after trans-urethral resection of a bladder
tumour (TURBT) is given. According to the EAU guideline on
NMIBC, a single post-operative instillation (SPI) with chemo-
therapy, a 1-year protocol with chemotherapy or immuno-
therapy with bacillus Calmette–Gue´rin vaccine (BCG), or
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instillations with BCG for 3 years should be given for low,
intermediate and high risk disease, respectively [1]. However,
in the above-mentioned CUETO risk tables for recurrence and
progression, these instillation protocols were already taken into
account, and still recurrence rates are high. Moreover, a world-
wide shortage in BCG has currently evolved. The shortage is
even more stringent because of the importance of BCG in
patients at high risk for progression to MIBC.
For these reasons, extensive research has been performed
to improve therapies in both adjuvant and neo-adjuvant
settings to prevent recurrence and progression, reduce the
intensity of follow-up, and to maximise bladder preservation
rates, thus prolonging the patient’s quality of life and survival.
A new treatment modality is electromotive drug administra-
tion (EMDA) [4], in which iontophoresis is being used for
improving tissue penetration by the chemotherapeutic drug.
Another strategy is photodynamic therapy (PDT), which uses
the interaction between absorbed light and a retained
photosensitising agent to destroy tissue, although it is
infrequently applied. A final new and promising strategy is
hyperthermia combined with intravesical chemotherapy.
Hyperthermia
The potential value of hyperthermia in treating cancer was
first suggested in 1866 by a German physician after he noted
disappearance of a sarcoma with a high fever due to
erysipelas. The use of hyperthermia in the management of
bladder cancer had not received much attention until halfway
through the 20th century. During this period, hyperthermia
was tested as a solitary treatment by recirculating hot fluid in
the bladder. It proved to be marginally effective in reaching
complete response (CR) even with temperatures of up to
80 C [5]. Therefore, combinations of hyperthermia with
radio- or chemotherapy were explored.
Techniques of establishing intravesical hyperthermia have
developed since. At present, four main techniques exist. All of
these combine hyperthermia with intravesical chemotherapy.
The first technique makes use of the before-mentioned
recirculation of fluid heated outside of the body, such as the
UniThermia [6] or Combat BRS systems [7] do. Secondly, a
relatively new technique which is still in the pre-clinical phase
uses magnetic fluid in combination with magnetic resonance
for heating [8]. The third and fourth more extensively
investigated techniques make use of radiofrequency (RF)-
induced hyperthermia. This can be applied from outside of the
body (deep external hyperthermia, e.g. a BSD-2000 device
[9]) or, as is discussed in this manuscript, with an intravesical
RF-emitting antenna (Synergo [10]) device.
The goal of this review is to provide an overview and
reflection on the current status of RF-induced chemo-
hyperthermia (CHT). Since a systematic review covering
literature up to January 2011 exists [11], we intend to give an
update based on the newly acquired knowledge.
Evidence acquisition and synthesis
A literature search in MEDLINE, Embase and Cochrane
databases was performed on 30 September 2015, resulting in
papers published from 1950 to 29 September 2015. Key
search terms used (as well as synonyms, abbreviations, and
entry terms/MeSH terms) were ‘bladder cancer’, ‘hyperther-
mia’, ‘chemohyperthermia’, and ‘radiofrequency’. Only titles
and abstracts were searched. Searches with these key terms
were combined with the appropriate Boolean operators.
Relevant conference abstracts were also searched for manu-
ally. ClinicalTrials.gov identified only one additional relevant
study regarding overactive bladder symptoms after Synergo
treatment which is currently recruiting.
Although this review is not a systematic review, it is based
on a very sensitive search. Titles and abstracts of the search
result were subsequently scanned for relevance. Where
applicable, authors and experts were asked for additional
information. Manuscripts were selected for further review if
an English abstract was available, if it concerned RF-induced
CHT, or in some cases, if it concerned intravesical hyper-
thermia with a very similar rationale such as conductive
heating or deep external RF-induced hyperthermia.
Clinical trials regarding intravesical RF-induced CHT were
evaluated and ordered in an overview to facilitate a compre-
hensive comparison. This overview focuses on clinical trials
published after the systematic review of Lammers et al., and
thus can be seen as a sequel of the table presented in that
publication [11].
No meta-analysis was performed because the newly
published manuscripts since January 2011 did not compare
RF-induced CHT with other treatments, or were too few for
pooling data [11]. Since most chemo-hyperthermia treatments
are performed with mitomycin C (MMC), the abbreviation
CHT in this manuscript is used for the combination of
hyperthermia with MMC unless otherwise stated.
Technical implementation (the Synergo device)
The only currently available device applying intravesical RF-
induced hyperthermia is the Synergo system, which has
been described in detail previously [10]. In short, local
hyperthermia is accomplished by a 915-MHz intravesical
microwave applicator heating the bladder wall. This applica-
tor is located in the distal end of a three-way transurethral 20F
catheter with Tiemann tip, containing a lumen for inflation of
the balloon, a lumen for fluid introduction, and another lumen
for outflow of fluid. Three thermocouples are tangentially
distended from the catheter tip to measure temperature at the
bladder neck, and the dorsal and lateral bladder walls. Two
additional thermocouples are incorporated more distantly
from the tip, measuring temperature in the proximal urethra
(Figure 1).
A bladder wall temperature between 41–44 C is preferable
[12]. Temperatures and RF power are monitored and
regulated on an external computerised unit to which the
catheter is connected, resulting in a closed circuit. This unit
also regulates the speed of the peristaltic pump and the
cooling of the fluid being pumped into the bladder. The latter
is done for urethral thermal protection.
Due to its favourable safety profile and the substantial
experience in combination with hyperthermia, MMC is being
used as the drug of first choice in chemo-hyperthermia
treatment. If MMC is not an option, epirubicin has been
accepted as a safe and efficient alternative. Typically,
treatment is given in two sessions of 20–30 min in which the
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aim is to achieve a temperature above 41 C during at least
20 min per session. Chemo-hyperthermia is most commonly
applied in a prophylactic protocol of 2 20 mg MMC or
2 25 mg epirubicin, also described as an adjuvant treat-
ment, or alternatively in an ablative protocol of 2 40 mg
MMC or 2 50 mg epirubicin, also known as neo-
adjuvant treatment. Dosages are dissolved in 50–60 mL of
saline or distilled water. Reasons for changing the instilled
fluid after 20–30 min are dilution by newly produced urine
and serum exudation, disintegration of the solution, and
that MMC absorption occurs mainly during the first
22 min [6,13]. After initial catheter insertion the bladder is
emptied. For minimisation of drug dilution patients are
instructed to limit fluid intake as much as possible before
each treatment.
For induction 6–8 weekly instillations are administered,
after which a maintenance period follows consisting of
instillations every 4–6 weeks for up to a year. During the
second year the interval is widened if no recurrence or
progression was seen. Follow-up cystoscopies are usually
performed every 3 months. Strictly taken, treatment can be
stopped after a disease-free period of 2 years, although no
studies have been performed to find the optimal treatment
duration. Nonetheless, many patients in our centres continue
treatment with longer intervals after a period of 2 years from
the first instillation.
Rationale and assumed mechanism
Although some in vitro and in vivo studies have been
performed to unravel the mechanism through which hyper-
thermia contributes to the anti-tumour effect, no uniform
theory yet exists. Nonetheless, results give direction to the
rationale for using hyperthermia in combination with
intravesical chemotherapy.
When hyperthermia alone is applied, this results in direct
damage to the DNA, RNA and proteins, and additionally
inhibits their synthesis resulting in a decreased proliferation
rate [4,7,14–16]. If subsequently repair mechanisms fail due
to altered intracellular metabolism, cell death and apoptosis
are accelerated [17]. These changes can be seen from
temperatures of 40.5 C and beyond, with magnitude inclining
with temperature [4,18]. Due to a change in intracellular
metabolism and resulting acidic and hypoxic micro-environ-
ment, a further sensitisation to both hyperthermia and
cytotoxic agents occurs. Beside these direct effects, the
immune system seems to be boosted [4,19], resulting in
increased cellular immune response and autovaccination
against tumour cells. Lastly, hyperthermia may increase
blood flow in normal surrounding tissue due to vasodilatation,
increasing MMC exposure. However, tumour vasculature is
less responsive and thus less efficient in dissipating heat,
resulting in a higher local temperature than in non-cancerous
cells. This possibly results in a higher treatment specificity for
cancerous cells. The same seems to be the case at cellular
level, since normal urothelial cells demonstrate more resist-
ance to CHT [15,17,20,21], although conflicting results are
reported [22].
By introducing chemotherapy to hyperthermia, this add-
itionally damages the vital cellular molecules in the absence
of a properly functioning repair mechanism, resulting in an
otherwise absent clinically relevant effect [16,17]. Thus,
hyperthermia leads to drug potentiation. This is demonstrated
by several in vitro studies which show a synergistic instead of
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Figure 1. Schematic illustration of the Synergo SB-TS 101 system during treatment.
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just an additive effect on cytotoxicity [18,23]. A possible role
in this synergy exists for p53 [16,17] and heat-shock proteins
[4]. Lastly, an increased tissue and cellular membrane
penetration is presumed but has not yet been confirmed.
Although an increased penetration is an intuitive hypoth-
esis, Wallner et al. [24] found that hyperthermic potentiation
of MMC activity was maximal if heating was done simul-
taneously to exposure, or up to 3 h following MMC exposure.
The fact that heating cells after MMC has been removed from
the medium still potentiates MMC cytotoxicity argues against
the importance of permeability or activation changes at
elevated temperatures; rather, it points to the importance of
alterations in damage repair processes. Moreover, RF-induced
CHT does not result in toxic plasma levels which might be
expected in increased tissue penetration [13].
At present, reason for choosing intravesical RF-induced
CHT instead of other ways of heating is the assumption that a
more controlled and effective heating, including a more
precise temperature measurement can be achieved, although
no good comparative studies have been performed. RF-
induced CHT has the advantage of being the most extensively
investigated form of applying intravesical hyperthermia, and
thus has a broader base of evidence. Fortunately, studies
regarding other forms of chemo-hyperthermia are emerging.
Clinical indications
Currently, RF-induced CHT can be discussed in NMIBC
patients at intermediate to high risk for recurrence and
progression. Roughly, three main indications exist, namely 1)
highly recurrent NMIBC under standard therapy, 2) therapy-
resistant CIS or other NMIBC, which means the tumour is
BCG-refractory, and severe co-morbidity or the explicit desire
of the patient for bladder sparing treatments, and 3) contra-
indications for BCG. As already mentioned in the introduc-
tion, these indications have been extended temporarily to
overlap the indications for BCG (high risk disease) in light of
the current BCG-shortage. Patients should not be given RF-
induced CHT if bladder volume is less than 150 cm3 (severe
bladder spasms and pain), if urinary bladder diverticulum
with a cumulative diameter of larger than 1 cm is present (risk
of perforation and MMC diffusion intraperitoneally), or if
catheterisation problems are expected.
The setting of RF-induced CHT can be prevention of
tumour recurrence (prophylactic, or adjuvant therapy), or
eradication of bladder tumour (ablative, or neo-adjuvant
therapy). Both have been used in studies, and results are
promising (described below).
Efficacy
Chemo-hyperthermia alone
Only a few comparative studies of RF-induced CHT with
MMC alone or with BCG exist. Most papers describe
experience with CHT alone, as a single-arm study.
Nonetheless, this does provide an impression of its general
efficacy. Regarding recurrence, for example, rates vary from
16–89%, see also Table 1 in this paper as well as Table 1 from
the systematic review of Lammers et al. [11,25–33]. Two
outliers are seen in this range, both representing studies with
patients not suitable and/or unwilling for cystectomy [29,34].
If these are excluded, a recurrence rate of 1650% remains
(22.650% if follow-up is at least 2 years). Moreover,
recurrence rates in the earliest studies are different from the
later studies performed, since the principal exploratory studies
all made use of CR or partial response scoring with
subsequent recurrence rates, regardless of dose and treatment
schedule [10,35], whereas later studies used specific ablative
or prophylactic treatment protocols.
Progression is reported less often than recurrence, since it
requires a longer follow-up of NMIBC. Nonetheless, some
figures are published: overall 0–36% show progression, and
when only studies with a follow-up of 42 years are
considered, the same figures apply [11,25–33]. Most of
these studies define progression as occurrence of MIBC.
Remarkable is the wide spread of progression rate, mostly
caused by the results of more recent publications [29,30,32].
These papers have a definition of progression which is much
broader than just the occurrence of MIBC. Sooriakumaran
et al. [30], for example, also include in the definition patients
with initiation of further treatment (BCG, cystectomy,
radiotherapy, diverticulectomy), extravesical disease, or dis-
tant metastases, reaching a progression rate of 36%. The study
of Kiss et al. used a cohort of patients who were not fit for, or
had refused cystectomy. Moreover, most patients did not
complete the treatment protocol due to adverse events [29]. If
these studies are excluded, a progression rate of 0–11.9%
remains [11,25–28,33].
Most studies published allow comparison of prophylactic
therapy with\ ablative therapy. CR after ablative therapy
ranges from 42–85.5%, with subsequent recurrence rates of
16–30.4% (follow-up ranging from 16–38 months).
Progression rate for complete responders varies from 0% to
27% [11,25,26,30–32]. See also Table 1. For prophylactic
therapy, recurrence rate varies from 15.6–56% and progres-
sion rate from 0–11.9% (follow-up ranging from 10–38
months) [11,25–28,31,33].
Although results in patients that have previously failed
intravesical therapy for NMIBC are contradictory, some
patients do seem to have additional benefit from CHT
treatment. For example, Lammers et al. [11] report on a
multicentre Italian project in which patients who have been
treated de novo with CHT do significantly better than those
who had previous intravesical instillations (2-year recurrence-
free survival (RFS) of 91% and 62% respectively, p¼ 0.006).
This finding is supported by a previous study showing a RFS of
75.4–58.8%, respectively [36]. However, in a different paper no
difference in response rate was seen in CIS patients failing or
responding to BCG [37]. Also in intermediate and high risk
patients in general, studies show no effect of previous BCG
failure [38,39]. Arends et al. describe their 10-year experience
in a cohort of 160 patients in which 81% of the subjects was
previously treated with BCG. Although not analysed separ-
ately, the overall 2-year RFS was 47% [28]. Thus, a substantial
proportion of pre-treated patients still benefits from treatment.
Bladder preservation rates have been described previously,
reaching a pooled rate of 89.4% [11]. In agreement with the
previous literature, more recent studies vary from 71–100% in
bladder preservation rate, depending on the treatment proto-
col used [25,27,29–32].
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Of further interest, Arends et al. evaluated the difference in
efficacy between MMC and epirubicin, both in a prophylactic
and an ablative protocol [28]. They found a pooled 2-year
RFS of 46% and 55% for MMC and epirubicin, respectively
(p¼ 0.30). No other groups have investigated efficacy of
chemotherapeutics other than MMC in CHT [17].
It needs to be noted that in all the above-mentioned rates, a
high level of methodological heterogeneity (mostly in patient
characteristics, treatment schedule and follow-up time) exists,
hampering the generalisability of these figures. Therefore,
cautious interpretation is warranted.
Chemo-hyperthermia vs. MMC alone
Up to this moment, four studies have been performed
comparing RF-induced CHT versus MMC alone. All four
were performed by the same author (although patients did not
overlap according to the author except for the long-term
results paper) and have been clustered in a meta-analysis in a
recent systematic review [11,20,21,40,41]. However, several
drawbacks are presented. One of these studies was a non-
randomised study; allocation in three treatment groups (i.e.
CHT, MMC alone, or EMDA) was according to patient
preference [40]. Moreover, different treatment duration and
drug concentrations were used. Three out of four studies were
performed in intermediate to high risk NMIBC patients, the
fourth in single, small (52 cm) stage Ta/T1 G1–2 patients.
In total, 26/93 patients (28%) had a recurrence in the
clustered CHT group, vs. 67/99 (67.7%) in the MMC alone
group. After meta-analysis this was corrected for different
weighting of studies, resulting in an overall risk ratio of 0.410
(95% CI, 0.290–0.579), indicating 59% less risk of recurrence
after CHT compared to MMC alone [11]. Although hetero-
geneity in the studied populations and methodological
shortcomings are present, this outcome does indicate a
substantial benefit of CHT over MMC alone.
CR rates were only reported in two studies comparing
CHT with MMC alone, showing 66% in both for CHT, vs.
22% (p¼ 0.001) and 27.7% (p-value not reported) in MMC
alone [20,40]. Progression, bladder preservation, and overall
survival were derived from two studies using the same cohort,
in which the latest paper reports the long-term outcomes of
the same intermediate to high risk patient cohort [21,41].
Over a median follow-up of 90 months (range 6–154), 2/35
patients (5.7%) treated with CHT and 3/40 (7.5%) treated with
MMC alone progressed. Bladder was preserved in 86.1% vs.
78.9%, respectively (p¼ 0.129), and overall survival was
29/35 (82.9%) vs. 31/40 patients (77.5%), respectively
(p¼ 0.558). No disease-specific deaths occurred.
Chemo-hyperthermia vs. BCG
Until now, no publications on the comparison of RF-induced
CHT vs. BCG exist, although an abstract of Arends et al. [33]
was presented at the latest conference of the European
Association of Urology (EAU) in 2015. In this abstract a
randomised controlled clinical trial comparing 1 year of RF-
induced CHT with 1 year of BCG in the adjuvant setting was
discussed. The study population consisted of 190 patients
with intermediate to high risk NMIBC, recruited over 11
centres between 2002 and 2012. A 24-month RFS of 81.8% in
the RF-induced CHT group, compared to 64.8% in the BCG
group was found on the per-protocol (PP) analysis
(p¼ 0.0216). The intention-to-treat analysis, however, did
not result in a significant difference (78.1% vs. 64.8%
respectively, p¼ 0.0803). In a specific analysis for CIS
patients only, a CR rate of 88.9% and 85.7% was found for
CHT and BCG, respectively (p40.1). Progression was
described in less than 3% in both groups (personal
communications).
Another interesting yet unpublished project is the HYMN
trial (ClinicalTrials.gov; NCT01094964). In this two-arm,
randomised, open-label and multicentre study from the UK,
RF-induced CHT is compared with BCG or standard therapy
as a second-line therapy in 104 patients with recurrent
NMIBC after a first-line induction or maintenance BCG
treatment. Whether a patient receives BCG maintenance or
standard therapy depends on the response to the first-line
BCG treatment. Primary outcomes were disease-free survival
time (DFS) in all patients, and CR rate at 3 months in patients
with CIS. Secondary outcomes will be RFS, progression-free
survival, overall survival (OS), disease-specific survival
(DSS), safety and tolerability, quality of life, and cost
effectiveness. Lastly, biomarkers of response to standard
and investigational treatment will be assessed. An abstract
was presented recently showing no difference regarding CR
and overall DFS [42]. The DFS in patients with papillary
disease alone at randomisation (n¼ 33), however, had an
improved DFS for RF-induced CHT compared to BCG or
standard therapy (HR 0.40, 95% CI 0.16–0.98, p¼ 0.05),
whereas with any CIS at randomisation (n¼ 71), DFS was
worse (hazard ratio (HR) 2.17, 95% confidence interval (CI)
1.15–4.08, p¼ 0.02). No difference in adverse events was
found.
The concept of CHT with a different technique has been
compared with BCG solely by Ekin et al. [43]. They
compared conductive CHT (n¼ 40) with BCG (n¼ 142) in
a retrospective propensity score-matched study in high risk
NMIBC patients and found a 2-year RFS in conductive CHT
and BCG groups of 76.2% and 93.9%, respectively
(p¼ 0.020). Conductive CHT treatment (HR 5.42; 95% CI
1.11–26.43; p¼ 0.036) and high-grade tumour (HR 4.60; 95%
CI 1.01–20.88; p¼ 0.048) were associated with an elevated
odds of tumour recurrence. In multivariate Cox regression
analysis, there was no significant difference between con-
ductive CHT and BCG in the odds of recurrence (p¼ 0.054).
There were no differences in progression.
Chemo-hyperthermia vs. radical cystectomy
Radiofrequency-induced CHT has also been compared with
the other gold standard, i.e. radical cystectomy (RC), by Nair
et al. [44]. This prospective single-centre review matched 103
high risk NMIBC patients treated with RF-induced CHT to 51
patients undergoing a RC. Patients in the CHT group had a
higher mean age and were more frequently treated with BCG
before therapy. Results are only available in an abstract,
showing a 5-year DSS of 85.2% and 74.6% in the CHT and
RC cohorts, respectively, and an OS of 61.9% vs. 68.4%.
For survival rates, a median follow-up of 40 months
(4–92 months) was accomplished. More complications
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(Clavian-Dindo score 42) were seen after RC (21%)
compared to CHT (0%), as well as more deaths (90-day
mortality of 4% vs. 0%, respectively). These results seem to
promote CHT over RC, although it needs to be noted that this
is not a randomised controlled and blinded trial, but a
matched design in which patient groups might have differed
significantly. Moreover, results regarding deaths and compli-
cations are not expected to be worse in CHT with this short
follow-up anyway.
Chemo-hyperthermia long-term efficacy
Just as studies comparing CHT with BCG are needed, studies
regarding long-term effects of RF-induced CHT are too. A
few studies have been performed with a median follow-up of
at least 60 months (5 years, Table 1) [28,29,32,41], although
only two of these studies were designed to study long-term
efficacy [32]. Colombo et al. [41] described an estimated 10-
year DFS of 52.8% for RF-induced CHT compared to 14.6%
for MMC alone (p50.0001). The estimated 5-year DFS for
CHT and MMC alone was 61.7% and 21.3%, respectively.
Both progression and RC rates did not differ significantly
between treatment groups (CHT 2/35 and 1/35, respectively;
RC 3/40 and 3/40, respectively).
Kiss et al. [29] had a median follow-up of 50 months,
although efficacy analysis was hampered by the high fall out
rate due to severe adverse events. They reported 6/21 patients
(29%) without recurrence after this follow-up period. Also
6/21 patients underwent a cystectomy. Regarding mortality,
2/21 died due to metastatic disease, and 5/21 due to other non-
cancer-related causes. Progression was not specified. At the
EAU conference 2015, Lu¨decke et al. [32] presented their
data regarding long-term efficacy of ablative RF-induced
CHT in 271 high risk NMIBC patients from 7 centres, with a
median follow-up of only 2.2 years (28 days–12.9 years), but
in some patients up to 12.9 years. CR was achieved in 76.1%,
and 76.8% remained tumour free for a mean of 28 months (2.4
months–10.8 years). Halachmi et al. [38], with a retrospective
study in 56 T1G3 NMIBC patients, found a 4-year recurrence
chance of 51%.
Last but not least, an as yet unpublished Italian multi-
centre, non-randomised, patient-for-patient matched study
was promoted and sponsored by the health provider
(Lombardy Region Health Care System) in order to compare
the outcomes of patients receiving adjuvant RF-induced CHT
or the current treatment according to the EAU guidelines.
Between January 2005 and July 2011 consecutive patients
were recruited into the treatment arm at 6 centres while for
the control arm the archived records of patients treated at a
single centre between January 2005 and December 2008 were
used. Only intermediate or high risk patients according to the
EORTC tables were accepted for comparative analysis. In all,
189 RF-induced CHT and 180 control patients were available
for the analysis of outcomes. At a minimum of 24 months of
follow-up, 24.9% and 38.3% of patients experienced a
recurrence in the RF-induced CHT and in the control arm,
respectively (p50.006). During the whole follow-up period
(median of 55.3 months), a sixfold rate of radical cystec-
tomies was registered in the control group compared to the
RF-induced CHT arm (20 and 3 cystectomies, respectively;
p¼ 0.0015) (Lombardia project, unpublished data, R.
Colombo, Milan, Italy).
Adverse events
An important factor in determining the value of RF-induced
CHT is the type and quantity of adverse events (AEs). For RF-
induced CHT, these can be divided into AEs seen during
treatment and AEs which prolong after treatment. Most
frequently seen AEs during treatment consist of bladder
spasms and pain (21.6% and 17.5%, respectively) [11]. Lower
urinary tract symptoms (LUTS) of storage (frequency, dysuria,
urgency, nocturia) (25.6%) and haematuria (6.0%) are the AEs
most commonly seen after treatment. Other commonly
observed AEs include cystitis-like symptoms (definitions
vary greatly, and overlap with LUTS) and allergic reactions/
rash (0–24%, with rashes included in the higher percentage).
Urethral strictures occur in only 0–10% of cases, with 3.5%
being mentioned in the recent systematic review [11,25–33].
Most adverse events are reported to be self-limiting and
reversible. Adverse event related drop-out rate is about 3.8%
[11], although one study reported a substantially higher drop-
out rate of 38%. In this study not all patients were fit for or had
refused cystectomy, implying that this was a highly selected
cohort with possibly a worse starting point [29].
During follow-up cystoscopy, an asymptomatic posterior
wall thermal reaction (PWTR) can be seen in almost all
patients [11,28]. Histological damage mainly occurs in the
tumour tissue, though leaving normal epithelium relatively
unharmed [35]. In the study by Rath-Wolfson et al. [45] using
anaesthetised sheep, histological changes in both RF-induced
CHT and control groups showed foci of oedema and haemor-
rhage with inflammation in the lamina propria and serosa. Foci
of desquamation of the epithelium were noticed in the treated
sheep. Histological analysis of the treated group showed no
significant differences compared to the control group.
Influence on endocrine homeostasis has also been tested,
in 11 patients receiving external RF-induced CHT, showing
none of the tested hormones (i.e. the thyroid, cortisol and sex
hormones) to be altered significantly [46]. Moreover, Paroni
et al. [13] investigated the plasma MMC concentrations after
20 mg and 40 mg of MMC with CHT, vs. both concentrations
without hyperthermia. They found a maximum plasma
concentration of 67.9 ng/mL after 45–60 min of treatment,
which was seen in the 40 mg MMC with CHT group. Median
value of systemic absorption for this group was 19.4 ng/mL,
compared to 5.56 ng/mL in the 20 mg MMC with CHT-group.
These values were significantly higher than those after MMC
alone with the same dose. All measured plasma concentra-
tions were well below the threshold for myelosuppression (i.e.
400 ng/mL).
In comparison with MMC instillations, and based on the
four previously mentioned papers comparing MMC alone to
RF-induced CHT, local toxicity was slightly higher in CHT,
although the difference was not significant [20,21,40,41].
Only one of these four studies found significantly more pelvic
pain and PWTR in the CHT group [21].
When comparing RF-induced CHT with BCG instillation,
more allergic reactions, pain, bladder spasm, strictures,
catheter issues and PWTR are found for CHT, compared to
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more fever, fatigue, arthralgia, haematuria, incontinence and
frequency in BCG treatment [33].
Altogether, it seems that toxicity after CHT is higher than
after MMC alone, whereas inadequate reporting hampers
comparison with other treatments. Based on just one confer-
ence abstract, toxicity in CHT compared to BCG is not
necessarily higher, but is mainly characterised by different,
instead of more frequent, AEs.
Critical appraisal and future perspectives
With 15 years of experience, RF-induced CHT has become a
commonly applied treatment modality in our centres.
Nonetheless, few properly designed randomised, controlled
clinical trials have been performed to date. As a consequence,
high level evidence for efficacy and adverse events remains
limitedly available and RF-induced CHT is still considered an
experimental form of therapy. This is one of the reasons why
centres hesitate to use this modality. Randomised controlled
clinical trials are being executed though, with some being
submitted and others being presented at conferences (which
are described earlier in this review).
Another conceivable reason for reservations regarding
intravesical RF-induced CHT could be the amount of adverse
events seen during and after treatment. However, within the
current indications, patients often have BCG or radical
cystectomy as the only alternatives. Logically, adverse
events and complications due to radical cystectomy are
more severe than in the case of RF-induced CHT [44].
Regarding BCG instillations, patients suitable for RF-induced
CHT often failed BCG or were BCG-intolerant. In deciding
which treatment modality should be used, one must be
conscious of the, albeit different, potentially serious or
frequent adverse events of BCG.
Costs of intravesical RF-induced CHT are regarded as
being substantial, although previously mentioned costs in
other papers are outdated [47]. One study on conductive
heating with the UniThermia device mentions device costs of
about E42 000 compared to E90 000 for the Synergo
console. Disposable UniThermia catheters cost about E200
each, compared to E600 for the three-way catheters used in
the treatment with Synergo [6]. However, this estimation for
Synergo costs is too high. Total costs per treatment vary
from about E650 to E850 in our centres, depending on the
drug and dose used (MMC or epirubicin), and include
dispersed acquisition costs.
No studies on cost-effectiveness in RF-induced CHT have
yet been published. However, the Lombardia project men-
tioned above attempted for the first time to assess the cost–
benefit ratio of RF-induced CHT. The cost-related model was
designed in order to simulate treatment outcome and cost in
100 patient pairs over a period of 10 years. One of the patients
in each pair was treated by RF-induced CHT and the second
according to current EAU guideline recommendations. Based
on this model, RF-induced CHT is expected to reduce the
overall cost for treatment of intermediate and high risk
NMIBC at long-term (5-10 years) follow-up compared to
current treatments. The cost/effectiveness of RF-induced
CHT treatment is currently under evaluation from the health
provider in view of its possible total reimbursement in the
routine clinical practice (Lombardia project, unpublished
data, R. Colombo, Milan, Italy).
Besides costs, some important obscurities in current
knowledge remain. For starters, it would be informative to
have data on the effect on quality of life in CHT-treated
patients compared to BCG or MMC treated, or even radical
cystectomised, patients. As written in the Evidence acquisi-
tion and synthesis section above, most of the research has
been performed with MMC. Epirubicin has been described in
only a few studies, and no good comparison with MMC was
possible [28]. Moreover, no evidence yet exists regarding
treatment duration. Although consensus exists for starting
treatment with an induction course and subsequently giving a
maintenance scheme of a combined total of 2 years, many
patients are treated for longer periods [11]. Studies addressing
all these issues would be most valuable.
Studies on different forms of achieving hyperthermia are
being performed, and authors have been increasingly publish-
ing their results in the past 2 years. Almost all make use of the
conductive heating technique, reaching an efficacy of 18–41%
for recurrence rates, 10.3–18% for progression rates, and have
about 50% of grade 2 adverse events, with 9.2–14.3% showing
grade 3 AEs (Common Terminology Criteria for Adverse
Events (CTCAE) version 6) [6,7,43,48]. Nonetheless, com-
parative studies of RF-induced CHT with these new forms of
(conductive) heating are important for determination of the
superior hyperthermic treatment in the future.
The place of RF-induced CHT in future NMIBC manage-
ment will partly be shaped by conclusions on the above-
mentioned issues. However, more ways of improving pharma-
cokinetics, drug exposure and pharmacodynamics will likely
have an important share as well.
Conclusion
Radiofrequency-induced chemo-hyperthermia remains a pro-
mising treatment modality which appears to be a potential
alternative to BCG immunotherapy. It can also be used in
patients unfit to undergo radical cystectomy, or to prolong
bladder preservation time. Adverse events and safety profile
seem to be acceptable in the context of the indication for RF-
induced CHT. Nonetheless, a more solid scientific basis is
needed to define the position of RF-induced CHT in relation
to other hyperthermic treatment modalities and in relation to
the newly emerged non-hyperthermia treatments.
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